Wall Street slips heading into holiday
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street rallies, Dow closes at record on Iran talks optimism
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Cantor Fitzgerald Reiterates Overweight on UnitedHealth Group (UNH) Following 8-K Filing
December 26, 2017 7:55 AM ESTCantor Fitzgerald reiterated an Overweight rating and $235.00 price target on UnitedHealth Group (NYSE: UNH) following the company's 8-K filing. The filing indicates that the company has "signed a definitive purchase agreement and intends to launch a tender offer for Empresas Banmédica, an initial step toward... More
Celgene (CELG) PT Lowered to $130 at Stifel; 'Revlimid Plus Ritxuan did not Achieve Superiority with Co-Primary Endpoints'
December 22, 2017 8:18 AM ESTStifel lowered its price target on Celgene (NASDAQ: CELG) to $130.00 (from $149.00) while maintaining a Buy rating, following the company's announcement regarding an update of Phase 3 trial Revlimid (Revevance).
Analyst Thomas Shrader notes a cautious outlook on the shares, commenting "that Phase III trial... More
